THE CONOLIDINE DIARIES

Our profiling and comparison of your steps of conolidine and cannabidiol with recognised pharmacological brokers predicted a MOA shared with Cav2.2 channel blocker, ω-conotoxin CVIE.2020). ACKR3 features as a 'scavenger' that 'traps' the secreted opioids and stops them from binding to the classical receptors, thus dampening their analgesic action